zn-a-1041
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2020 (NCT05593094)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07051993 | Phase 1 | Jun 27, 2025 | Genentech |
| NCT04487236 | Phase 1 | Oct 15, 2020 | Peking University |
| NCT05593094 | Phase 1 | Oct 15, 2020 | Duke University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Genentech | For profit | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1